This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Risperidone

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Risperidone is aan antipsychotic agent which has mixed dopamine D2 receptor and serotonin S2 receptor blocking activities.

  • indicated for first onset and acutely relapsed patients
  • the blocking of 5HT2 receptors means that it may also selectively relieve negative symptoms - other drugs with the same receptor action have been shown to do this
  • has a lower incidence of extra-pyramidal side-effects than conventional anti-psychotics

Note that (1):

  • risperidone is not licensed for the treatment of behavioural symptoms of dementia
    • risperidone is not recommended for the treatment of behavioural symptoms of dementia because of an increased risk of cerebrovascular adverse events (including cerebrovascular accidents and transient ischaemic attacks
      • data from randomised clinical trials conducted in the elderly (> 65 years) patients with dementia indicate that there is an approximately 3-fold increased risk of cerebrovascular adverse events (including cerebrovascular accidents and transient ischaemic attacks) with risperidone, compared with placebo. Cerebrovascular adverse events occurred in 3.3% (33/989) of patients treated with risperidone and 1.2% (8/693) of patients treated with placebo. The Odds Ratio was 2.96 (1.33, 7.45 - 95% confidence interval)

Reference:

  1. Janssen-Cilag Limited (12th March 2004). The risk of cerebrovascular adverse events in elderly patients with dementia:- important changes to the Summary of Product Characteristics relating to the use of risperidone.
  2. Prescribers' Journal (1999); 39 (3): 154-159.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page